PHAR Stock Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Pharming Group N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €10.45 |
52 Week High | €16.71 |
52 Week Low | €9.27 |
Beta | 0.73 |
1 Month Change | -3.69% |
3 Month Change | -17.65% |
1 Year Change | -4.91% |
3 Year Change | -18.49% |
5 Year Change | n/a |
Change since IPO | -37.43% |
Recent News & Updates
Shareholder Returns
PHAR | US Biotechs | US Market | |
---|---|---|---|
7D | 12.0% | 0.4% | 1.0% |
1Y | -4.9% | 0.9% | 21.9% |
Return vs Industry: PHAR underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: PHAR underperformed the US Market which returned 24.9% over the past year.
Price Volatility
PHAR volatility | |
---|---|
PHAR Average Weekly Movement | 11.4% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PHAR's share price has been volatile over the past 3 months.
Volatility Over Time: PHAR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1988 | 382 | Simon de Vries | www.pharming.com |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Pharming Group N.V. Fundamentals Summary
PHAR fundamental statistics | |
---|---|
Market cap | US$636.45m |
Earnings (TTM) | -US$10.55m |
Revenue (TTM) | US$245.32m |
2.6x
P/S Ratio-60.3x
P/E RatioIs PHAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHAR income statement (TTM) | |
---|---|
Revenue | US$245.32m |
Cost of Revenue | US$25.21m |
Gross Profit | US$220.10m |
Other Expenses | US$230.65m |
Earnings | -US$10.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
Earnings per share (EPS) | -0.016 |
Gross Margin | 89.72% |
Net Profit Margin | -4.30% |
Debt/Equity Ratio | 63.3% |
How did PHAR perform over the long term?
See historical performance and comparison